IVEH - IVES HEALTH CO - To Post Summary of the Landmark Java Project - That Proves "T-Factor" Increases T-Cell (CD-4) Cell Count - In HIV/AIDS Patients
New York, New York, Feb 20, 2001 (Market News Publishing via COMTEX) -- Ives
Health Company announced that in order to facilitate the public's unbelievable
response to T-Factor(R) and the Java Project, the Company is making a brief
summary of the Project, that will include patient profiles, available at
iveshealth.com.
The results of this groundbreaking study are now gaining worldwide attention
from both the investment and healthcare communities.
Keith Ives, President and Founder of Ives Health Company, stated: "The sheer
amount of excitement surrounding this product has been daunting. When we found
the product three years ago, T-Factor(R) was an unsightly paste that had to be
administered through a stomach tube. Thanks to years of dedicated research, we
have solved the problems of putting the formula in a pill that is easily
swallowed, and preserving that formula until it reaches the consumer. This has
required both hard work and vision on the part of our team, our investors, and
our clients. We could not be more enthusiastic about helping to improve the
lives of hundreds of millions of people who are infected with HIV."
T-Factor(R) was released to the public on February 13, 2001, on Ives Health
Company's website at iveshealth.com. Mr. Ives continued: "Because the
product has almost no side effects, we are trying to get the word out through
HIV and AIDS support groups around the country. We are also attempting to have
the product tested and notarized by a celebrity who is battling HIV. HIV is a
terrible virus and the enthusiasm that the investment community is showing over
T-Factor will help us get the word out to millions of people who desperately
need our help."
About the Java Project and T-Factor(R)
The Java Project was a landmark AIDS study carried out by Dr. Slayton-Bedeen, an
Immunologist and T-Factor(R) Founder, along with the World Health Organization
in Jakarta and Bangkok. The project found that new hormonal inhibitors of the
Human Immunodeficiency Virus (HIV), like T-Factor(R), might initiate profound
and sustained suppression of HIV replication. The T-Factor(R) formula was
administered to 186 HIV-Positive patients of Asian descent with elevated HIV RNA
and decreased CD-4 counts, over a period of 24 weeks. The results were dramatic,
with over 80% of patients experiencing documented decreases in HIV RNA and
enhanced CD-4 counts after 24 weeks.
The T-Factor(R) formula, acquired by Ives Health Company in 1998, is
all-natural, has virtually no side effects, and is readily available over the
Internet at iveshealth.com. T-Factor(R) costs less than $3.00 per day
versus $80.00 per day for current HIV drug therapies. New studies are on-going
in the United States and recently began in Europe. Findings will be released as
the data is reported and validated. T-Factor(R) is not a cure for HIV, but is
intended to extend the lives of those inflicted with the virus.
About Ives Health Company
Ives Health Company is committed to improving consumers "Total Health" through
their high-quality natural remedies and homeopathic medicines. Ives product
formulations use 98.3% pure natural ingredients and deliver an astounding 90% of
the active ingredients into the bloodstream. The Company's products compete in
the $99.2 billion diet and nutritional product arena under the following branded
names: Pharmacy Health and Diet Program(R), T-Factor(R) Immune Enhancement
System, Vegi Bears(TM) (a nutritional snack) and other natural remedies for
Aches & Pains, Acne (a non-topical oral treatment), Allergy, Antacid, Arthritis,
Cough & Sore Throat, Energy, Headache, Sinus, PMS relief, Prostate relief, and
Cholesterol control, among others. Please visit iveshealth.com to
purchase or to learn more about the Ives family of homeopathic medicines, weight
management and natural remedy products.
This news release includes "forward-looking statements" that include risk and
uncertainties. The forward-looking statements in this release are made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Actual results may differ materially due to a variety of factors,
including without limitation the Company's ability to produce and market
products and/or services and other risks detailed from time to time in their
Company's reports filed with the Securities Exchange Commission. Please consult
with your physician prior to starting a weight loss program.
CONTACT: TEL: 775/828-6576 For Ives Health:
Strategic Communications
Investor Relations
Internet: www.iveshealth.com
URL: www.iveshealth.com |
